Background: Fanconi anemia (FA) is a condition characterized by genetic instability and short stature, which is due to growth hormone (GH) deficiency in most cases. However, no apparent relationships have been identified between FA complementation group genes and GH. In this study, we thereby considered an association between FA and Laron syndrome (LS) (insulin-like growth factor 1 [IGF-1] deficiency).
INTRODUCTION

F
anconi anemia (FA) is an inherited disorder associated with chromosomal instability, bone marrow failure, developmental defects and a predisposition to cancer. [1] [2] [3] [4] Patients with FA present with endocrine abnormalities including short stature with or without growth hormone (GH) deficiency, hypothyroidism, midline brain abnormalities, abnormal glucose-insulin metabolism, obesity, dyslipidemia and metabolic syndrome. 5, 6 Although a previous study reported shorter stature among patients with endocrine abnormalities compared with those without such abnormalities, 7 to date, only GH deficiency has appeared to correlate significantly with short stature. 8 Herein, we present the first investigation of an association between characteristic features of insulin-like growth factor 1 (IGF-1) deficiency and FA.
Laron syndrome (LS), or primary GH insensitivity (GHI), is characterized by GH receptor deficiency (most common), defective GH-GH receptor signal transduction, defective IGF-1 synthesis, IGF-1 receptor deficiency and defective IGF-1-IGF-1 receptor signal transduction defects. 9 Epidemiologically, LS features a strong ethnic bias (490% of cases occur in ethnically Jewish populations). 10 Clinically, uterine growth and length at birth are slightly decreased in neonates with LS (42-47 cm) than in their healthy counterparts (49-52 cm). The symptoms of LS worsen throughout childhood, leading to the retardation of both skeletal maturation and organ growth. 11 Observed growth abnormalities in LS patients without IGF-1 treatment include a reduction in the average expected postnatal growth by approximately 50% during the first years of life; reduced brain size, along with a prominent forehead, reduced vertical facial dimension and hypoplasia of the midface and nasal bridge; reduced cardiac size; acromicria; underdeveloped muscular system and consequent walking delays in 75% of patients; osteopenia at all stages (despite normal sex hormone status) with increased avascular necrosis of the femoral head; impaired skin, hair and nail growth; blue sclera due to reduced connective tissue thickness, allowing visualization of the underlying choroid; puberty delay of 3-7 years; retarded dental maturation and high-pitched voice.
12
A 21-year-old female Mexican patient with a genetic diagnosis of FA was referred to our research department for an evaluation of her short stature. The patient had been born to healthy, consanguineous Mexican parents at 34 weeks' of gestation with a birth weight of 1800 g and length of 45 cm. At birth, she presented with respiratory distress due to hyaline membrane disease, which was treated with assisted ventilation for 1 week without complications. She was also diagnosed with congenital dislocation of the hip ( Figure 1A and B) , which was addressed with conservative treatment. During her early childhood, she failed to thrive and she was further diagnosed with anemia, but did not respond to iron supplementation treatment. At the age of 4, she was referred to a hematologist for bone marrow aspiration; the aspirate revealed hypocellular bone marrow with a normal karyotype, leading to a molecular diagnosis of FA. Throughout her life, she suffered from multiple episodes of coughing with breathlessness and was diagnosed with asthma; a thoracic computerized axial tomography scan indicated a restrictive pattern.
DNA Extraction and Quantification
Genomic DNA was extracted from the patient's peripheral blood using the Easy-DNA kit (Invitrogen, Carlsbad, CA) and stored at À201C until analysis. DNA quality was initially assessed using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
Library Preparation and Next-Generation Sequencing Analysis
The patient's DNA samples were fragmented, tagged, amplified and pooled using a TruSight One library enrichment kit (Illumina Inc., San Diego, CA) according to the manufacturer's protocol to yield 12.5 pM of loading library sample. Next-generation sequencing was performed using a MiSeq desktop sequencer and MiSeq Reagent kit v3 flowcell (Illumina Inc.). Three hundred paired-end run cycles with a Phred quality threshold 430 were executed. Detected genetic variants were aligned against Homo sapiens, hg19, build 37.2 and analyzed using Variant Studio 1.0 software (Illumina Inc.). The variant evaluation was restricted to genes associated with short stature and FA. All mutations selected for analysis were missense or nonsense variants with a predicted effect of damage according to scale-invariant feature transform and polymorphism phenotyping algorithms, read depth 4 20 and Phred quality threshold 4 30 (1:1000 probability of an incorrect base call).
RESULTS
Clinical Features
A physical examination of the 21-year-old woman patient yielded a height of 130 cm (À5 standard deviations [SDs]) and a weight of 34 kg (À3 SDs) ( Figure 1G -I).
The patient had short symmetrical limbs, abnormal dental development ( Figure 1C ) and normal skin and nails. A genital examination revealed stage V development according to the Tanner scale.
Radiological studies revealed marked scoliosis ( Figure 1D and H) without subluxation or rotation; however, the patient had been diagnosed at birth with congenital subluxation of the hip ( Figure 1A and B) and skeletal maturation retardation ( Figure 1E and F), where chronological age of the radiographs is 3 years and 6 months and bone age is 2 years and 3 months, having a delay of 1 year and 3 months.
Biochemical Studies
The laboratory analysis revealed a normal hemoglobin level (12.3 g/dL), mean corpuscular volume of 101 fL, hematocrit (Hct) of 35.7%, platelet count of 80,700/mL and total cell count (leukocytes ¼ 3430/mL); the hormonal profile included a normal thyroid panel (triiodothyronine [T3] ¼ 1.24 ng/mL; thyroxine [T4] ¼ 9.00 mg/dL, thyroid-stimulating hormone ¼ 1.25 mUI/mL; free T4 ¼ 1.23 ng/dL). The serum IGF-1 level was 95 ng/mL (o3rd percentile), the serum IGFBP3 level was 3.0 mg/dL (1.8-4.6 mg/dL) and the basal GH level was 4.6 ng/mL, with no response to clonidine stimulation.
Molecular Diagnostics
Six heterozygous missense variants were identified in different FA complementation groups (Table) . These The next-generation sequencing results revealed 2 heterozygous missense variants that could explain the LS phenotype and features. These missense variants were identified in the STAT5B gene (NM…c.707C4A) and IGFBP3 gene (NM…c.332G4A) (Table) ; in addition, a nonsense variant was identified in the IGFBP3 gene (NM…c.190G4T) (Glu64X). None of these variants had been reported in the NCBI Short Genetic Variations database.
DISCUSSION
The patient was diagnosed with FA and LS based upon the clinical features and results of biochemical and molecular analyses. Gene Variants Associated With FA FA is a genetic disorder characterized by bone marrow failure at an early age. Patients also exhibit increased risks of developing malignancies, myelodysplastic syndrome and acute myeloid leukemia. 1, 13, 14 FA is a genetically heterogeneous disease, and at least 15 genes have been deemed responsible for the known FA complementation (FANC) groups (A, B, C, D1, D2, E, F, G, I, J, L, M, N, O and P). Among these 15 complementation groups, FANC-A (60-70%), FANC-C (up to 14%) and FANC-G (up to 10%) collectively account for 490% of the FA groups. Most of the resulting proteins assemble into a multiprotein core ubiquitin ligase complex required for monoubiquitination of the FANC-D2-FAN-CI dimer that loads onto chromatin in response to DNA damage. 15 A mutation in any of these genes will lead to FA.
The patient in this study harbored a mutated version of PALB2; this gene, which is well known for its involvement in the development of FA, plays a critical role in homologous recombination repair and serves as a molecular scaffold during the formation of the BRCA1-PALB2-BRCA2 complex, which is essential for homologous recombination 16 ( Figure 2 ). It was difficult to classify our patient into a specific FA complementation group because she harbored heterozygous missense variants of various FA genes, including FANCL, FANCG, FANCI, PALB2 (FANCN) and a compound heterozygous variant of the FANCA gene (Table) .
Gene Variants Resulting in an IGF-1 Deficiency Phenotype
Most reported cases of GHI involve mutations in the extracellular domain of the GHR gene. 17, 18 However, several cases have been found to involve mutations in the STAT5b gene that lead to GHI and a condition that resembles LS. [19] [20] [21] [22] As noted above, the patient in this case harbored a heterozygous missense mutation in the STAT5B gene.
The transcription factor STAT5B regulates the expression of IGF-1, IGF2, IGFBP3 and ALS (Figure 3 ). Approximately 90% of circulating IGF-1 is bound to IGFBP3, which forms a ternary complex with an acid-labile subunit. This ternary complex primarily regulates IGF-1 bioavailability. 23 Our patient carried 2 heterozygous mutations within conserved regions of exon 1 of the IGFBP3 gene.
The patient exhibited low serum levels of IGF-1 and IGFBP3, in agreement with previous reports of STAT5B mutation. She also displayed postnatal growth retardation, with a height of 130 cm (À5 SDs); this short stature was slightly less severe than that of other reported cases of GHI and STAT5B mutation (approximately À7.0 SDs) in a young female 20 and male subject. 19 In a given patient, mutations in either or both copies IGFBP3 may inhibit formation of the ternary complex formed by IGF-1, IGFBP3 and acid-labile subunit and thus decrease the bioavailability and half-life of IGF-1, an explanation that could account for the observed LS features that could not be attributed to the biochemical levels of GH and IGF-1.
The association between FA and low IGF-1 levels has been previously recognized. 24 GH deficiency has been proposed as the mechanism underlying this dysregulation. However, previous reports have not included a molecular (genetic) characterization of the full GH-IGF-1 axis. 6, [24] [25] [26] [27] [28] [29] Interestingly, FA patients in whom short stature has been attributed to GH deficiency do not reliably develop a phenotype similar to pituitary dwarfism. Rather, these patients exhibit a similar phenotype to that of Laron dwarfism, which was observed in our patient. We conducted a genetic analysis of GH secretion-stimulating pathway components (e.g., GHRH, GHRHR and somatostatin) in our patient and found no defects; accordingly, we were unable to explain a pituitary dwarfism. Even so, this finding, together with the observation of low GH levels, does not explain the low IGF-1/IGFBP3 levels or the LS characteristics and phenotype. The patient was diagnosed according to clinical, phenotypic, molecular and biochemical features with a dual pathology of LS and FA. For patients with FA, and in accordance with the above, we propose IGF-1 treatment as a valid option to address (1) short stature (if still within growth age, which is not the present case); (2) immune dysfunction (e.g., recurrent infections); (3) hypocellular bone marrow; (4) metabolic dysregulation in early adulthood; and (5) somastotinergic tone restoration.
We also underscore the need for molecular diagnostic tests of the GH-IGF-1 axis at the time of FA diagnosis to clarify the reason for short stature, as the FA complementation gene groups per se do not explain this characteristic feature. 
IGF-1 Therapy and FA
The current treatment approach for FA primarily comprises hematopoietic stem cell transplant. 30 The potential of granulocyte colony-stimulating factor and erythropoietin to yield improvements in hematopoietic function has been studied in a mice model of FA. However, these agents have proven to be effective solely in the short term. 31 A previous report observed that some FA patients with short stature are hyporesponsive to GH treatment. 28 Accordingly, GH would be an ineffective treatment for short stature conditions related to GH resistance. 32 IGF-1 plays a well-known and relevant role in erythropoiesis in murine and cell models; however, in humans it has only been indirectly linked. [33] [34] [35] [36] In fact, IGF-1 has been therapeutically linked to several hematologic conditions, particularly those involving radiation toxicity in mice. 37, 38 Radiation-induced DNA damage results in genomic instability and reactive oxygen species (ROS) generation. 39 This phenomenon is quite similar to the genetic alterations observed in FA patients due to the lack of DNA repair proteins. 40 Studies in mice have shown that IGF-1 can mitigate hematopoietic toxicity after lethal radiation doses, even when administered 6 hours postirradiation. 38 In another study, IGF-1 was shown to promote reorganization of the bone marrow microenvironment, specifically osteoblastic niche expansion, and thus enhance long-term hematopoietic stem cell engraftment after murine bone marrow transplantation. 37 Likewise, IGF-1 has been shown to exert protective effects in radiated CD34 þ hematopoietic cells by decreasing ROS generation in the microenvironment and inhibiting the mitochondrial pathway of apoptosis of mice. 39 In the light of these findings, the rationale behind administering IGF-1 to improve the bone marrow failure observed in FA patients seems sensible, given the ability of this agent to reduce ROS production and directly enhance erythropoiesis and lymphopoiesis in animals and human ex vivo cultures. [41] [42] [43] [44] [45] In one study, GH deficiency idiopathic-related anemia children were treated with GH and positive effects on erythropoiesis were found, 35 recognizing the important role of IGF-1 in these effects (as GH stimulates local and systemic IGF-1 production). However, our patient, due to mutations in STAT5b should be insensible to GH effects, thus pointing to IGF-1 as the choice of election. In the particular case of our patient, IGF-1 might not only augment the existing low levels of IGF-1, but could, in theory, also promote bone marrow and immune re-establishment. We encourage FA specialists to screen patients for GHI, always using low IGF-1 doses and carefully screening for tumor markers, as FA is commonly associated with tumorigenesis; the current prevalence of this condition among FA patients remains unknown, and it appears that substitutive therapy with recombinant human IGF-1 may improve the clinical outcomes of some patients.
CONCLUSIONS
Our patient could be classified as a dual-diagnosis case involving FA and LS. We understand that a diagnosis of LS might be surprising given the low GH levels. However, GH deficiency alone does not explain the patient's clinical features, which were more clearly explained by mutations in STAT5B and IGFBP3. This diagnostic association might be more prevalent than the currently recognized statistics, and may form the basis for a new screening methodology for FA patients. Although STAT5B and FA mutations have been independently described, their concurrence might have important implications for therapeutic patient management.
Functional tests, performed using either complementation or transfection, are needed to verify the effects of the reported mutations on protein function.
